PH vs REGN · P/E 28, rev $19.85B vs P/E 14, rev $14.34B
Parker-Hannifin Corporation (PH) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Parker-Hannifin Corporation (PH) is a specialty industrial machinery company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported PH revenue for 2025-06-30 was $19.85B. Net income was $3.53B. PH currently screens at market cap $91.89B and trailing P/E 27.7.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
PH currently screens at market cap $91.89B and trailing P/E 27.7. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the PH and REGN stock pages for the full models.
Not investment advice.